10-Q: AIM ImmunoTech Faces Liquidity Crisis, NYSE Relisting

AIM ImmunoTech reported increased net losses for the quarter, significant cash depletion, and a going concern warning, despite regaining NYSE American listing after a reverse stock split and securing new financing.

Summary

• Net loss for the three months ended June 30, 2025, increased to $2.794 million from $1.836 million in the prior year, a 52% increase.
• Net loss for the six months ended June 30, 2025, decreased to $6.499 million from $7.653 million in the prior year, a 15% decrease.
• Cash and cash equivalents decreased significantly to $476,000 as of June 30, 2025, from $1.701 million at December 31, 2024.
• Marketable investments also declined sharply to $359,000 from $2.276 million over the same period.
• Total current assets plummeted to $1.025 million from $4.176 million, while total current liabilities increased to $10.393 million from $9.535 million.
• The company reported a stockholders deficit of ($6.546) million as of June 30, 2025, worsening from ($1.322) million at December 31, 2024.
• A 1-for-100 reverse stock split was effected on June 12, 2025, to regain compliance with NYSE American listing requirements, leading to the reinstatement of trading on June 17, 2025.
• The AMP-270 Phase 2 clinical trial for pancreatic cancer has been placed on hold, and the Phase 2 study for advanced recurrent ovarian cancer was terminated due to lack of funding.
• A public offering on July 30, 2025, raised $8.0 million in gross proceeds, and a Streeterville Bridge Note was repaid early on August 1, 2025, for $285,000.

Sentiment

Score: 3

Explanation: The company faces severe liquidity challenges, a significant stockholders' deficit, and a going concern warning. While it successfully navigated a delisting threat and secured new financing, these are temporary fixes for underlying financial fragility. Clinical progress is mixed, with some positive updates but also trial suspensions due to funding. The overall financial health remains highly precarious, outweighing the positive clinical developments and recent capital raises.

Positives

• Net loss for the six months ended June 30, 2025, decreased by $1.154 million (15%) compared to the same period in 2024.
• Cash used in operating activities for the six months ended June 30, 2025, decreased by $3.931 million, indicating a reduced cash burn rate from operations.
• The company successfully regained compliance with NYSE American listing standards and trading was reinstated on June 17, 2025, following a 1-for-100 reverse stock split.
• Positive mid-year safety and efficacy update for the DURIPANC study (Ampligen with durvalumab) in pancreatic cancer, with 21% of subjects having progression-free survival >6 months and 64% overall survival >6 months in eligible subjects.
• Final clinical study results from AMP-518 for Post-COVID condition of fatigue support Ampligen as a potential therapeutic, particularly for subjects with moderate-to-severe fatigue.
• A new patent covering methods for manufacturing therapeutic double-stranded RNA (dsRNA) products, including Ampligen, was granted in June 2025, providing patent protection until 2041.
• A public offering closed on July 30, 2025, raising $8.0 million in gross proceeds, providing much-needed capital.
• The Streeterville Bridge Note was repaid early on August 1, 2025, for $285,000, taking advantage of an early repayment discount.

Negatives

• Net loss for the three months ended June 30, 2025, increased by $958,000 (52%) compared to the same period in 2024.
• Cash and cash equivalents decreased by $1.225 million during the six months ended June 30, 2025, ending at $476,000.
• Marketable investments decreased by $1.917 million during the six months ended June 30, 2025, ending at $359,000.
• Total current assets decreased by $3.151 million, while total current liabilities increased by $858,000, leading to a significant working capital deficit.
• Stockholders deficit worsened to ($6.546) million as of June 30, 2025, from ($1.322) million at December 31, 2024, falling further below NYSE American's $6.0 million equity requirement.
• Revenues from clinical treatment programs decreased by $25,000 (50%) for the three months and $49,000 (54%) for the six months ended June 30, 2025, due to fluctuating patient participation.
• The AMP-270 Phase 2 pancreatic cancer clinical trial was placed on hold and suspended due to a business decision.
• The Phase 2 study for advanced recurrent ovarian cancer was terminated due to lack of funding.
• The 401(k) safe harbor matching contribution was discontinued effective June 1, 2025.
• The ANMAT approval process for commercial sales of Ampligen in Argentina for CFS is delayed due to internal processes, and the partner, Filaxis, has shifted focus to oncology.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least one year due to incurred losses, net cash used in operating activities, and a working capital deficit.
• Failure to increase stockholders' equity to at least $6.0 million by June 11, 2026, could lead to delisting from the NYSE American.
• The company relies heavily on financing activities to fund operations and clinical trials, with no assurance of obtaining adequate future funding.
• Future funding may result in significant dilution to existing stockholders and could involve the issuance of securities with senior rights.
• Clinical trials are subject to many factors, including lack of regulatory approvals, study drug availability, and changes in priorities, with no assurance of success or favorable data.
• Operating in foreign countries carries risks, including difficulties in enforcing intellectual property rights and adverse effects from economic conditions like hyper-inflation and currency devaluation in Argentina.
• The production of new Alferon N Injection Active Pharmaceutical Ingredient (API) is on hold, and there is no definitive timetable to resume production, impacting potential future sales.
• Legal proceedings, such as the potential reinstatement of BioLife Plasma Services, L.P.'s counterclaim for $96,000, pose financial and operational risks.

Future Outlook

The company continues to prioritize clinical activities for Ampligen, particularly in pancreatic cancer, with the goal of supporting future New Drug Applications (NDAs) with the FDA or European Medicines Agency (EMA). It intends to seek collaborative grants for avian influenza studies and plans a comprehensive follow-up with the FDA regarding Ampligen for ME/CFS, adjusting its approach to specific symptoms. The company is actively seeking senior co-development partners with capital and expertise to commercialize its experimental drugs and Alferon N Injection. It anticipates needing additional funding to continue operations and for new or ongoing studies, and may access public equity markets when favorable. The validation of the polymer production process with Sterling Pharma Solutions is ongoing, which is necessary for future Ampligen manufacturing.

Management Comments

• Management believes all adjustments necessary for a fair presentation of its consolidated financial statements have been included and consist of normal recurring items.
• Management believes that the mitigating effect of its plans (to address going concern) is only considered if it is probable that the plans will be effectively implemented and will mitigate substantial doubt within one year.
• Management evaluated the conditions and significance in relation to the company's ability to meet its obligations and noted that all outstanding debt is current as of June 30, 2025.
• Management believes that the pre-clinical and clinical work to date, combined with the ever-growing threat of Avian influenza, strongly supports the decision to move forward with a second Ampligen and FluMist study in humans.
• Management believes that if Ampligen has the broad-spectrum antiviral properties it believes it has, it could be a very valuable tool as a therapeutic or treatment for variants of existing viral diseases, including COVID-19, or novel ones that arise in the future.
• Management believes that continued efforts to understand existing data, and to advance the development of new data and information, will ultimately support future filings for Ampligen and/or the design of future clinical studies that the FDA requested in a CRL.
• Management believes that the analysis of Ebola virus disease data supports a dual mechanism of action when Ampligen is used as a prophylactic therapy against Ebola Virus Disease.
• Management believes that the trial (intranasal Ampligen) is a critical step in ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
• Management believes that the final Clinical Study results from AMP-518 support Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for any follow-up clinical trial.
• Management believes that the absence of glycosylation (in recombinant alpha interferons) may be in part responsible for the production of interferon-neutralizing antibodies seen in patients treated with recombinant alpha interferon.
• Management believes it has sufficient Ampligen API to meet current needs but is continually exploring new efficiencies to maximize its ability to fulfill future obligations.
• Management believes that the information found on its website is not incorporated by reference into this Report and is included for reference purposes only.

Industry Context

AIM ImmunoTech operates in the highly competitive and capital-intensive immuno-pharma and biotechnology sectors, focusing on cancers, viral diseases, and immune-deficiency disorders. The company's strategy of developing Ampligen as a TLR3 agonist for various indications, including pancreatic cancer and Post-COVID conditions, aligns with broader industry trends seeking novel immune-modulating therapies. Its collaboration with AstraZeneca on the DURIPANC study and pursuit of grants for avian influenza research reflect the industry's move towards combination therapies and addressing emerging global health threats. However, the challenges in securing regulatory approvals, particularly with the FDA, and the significant financial requirements for clinical development are common hurdles in this industry. The termination of some trials due to funding issues highlights the precarious nature of R&D-focused biotechs without substantial revenue streams. The shift of its Argentinian partner, Filaxis, from CFS to oncology also reflects evolving market priorities within the pharmaceutical landscape.

Comparison to Industry Standards

• Ampligen was cited as outperforming two other TLR3 agonists (poly IC and natural double stranded RNA) in creating an enhanced tumor microenvironment for checkpoint blockade therapy in the journal of Cancer Research, by selectively reprogramming the tumor microenvironment without amplifying immune-suppressive elements.
• The Netherlands study on Ampligen for pancreatic cancer generated statistically significant data indicating extended survival well beyond the Standard of Care (SOC) when compared to well-matched historical controls, suggesting a competitive advantage in this difficult-to-treat cancer.
• The company acknowledges that 'some of the worlds largest pharmaceutical companies are also working on treatments and cures for different types of cancers,' indicating a highly competitive landscape where AIM ImmunoTech must differentiate its therapies.
• The positive preliminary results from the AMP-518 study for Post-COVID condition of fatigue, showing a clinically significant decrease in fatigue-related measures and improvement in cognition, suggest Ampligen's potential in an area with significant unmet medical needs, where many other therapies have limited efficacy.

Management Changes

Corporate Governance

Legal Proceedings

• On July 28, 2025, the Superior Court of Pennsylvania affirmed the September 10, 2024, Order dismissing the company's complaint against BioLife Plasma Services, L.P. Judgment was entered dismissing the case.
• The parties have 14 days to seek En Banc Review or further Appeal to the Pennsylvania Supreme Court or to take other action in the Common Pleas Court, including reinstatement of BioLife's counterclaim for $96,000.

Stakeholder Impact

• Shareholders: Experienced significant dilution from past and recent capital raises, and the 1-for-100 reverse stock split. Face ongoing risk of further dilution and potential delisting if the company fails to meet NYSE American equity requirements. The stock was suspended and moved to the Pink Open Market before relisting, impacting liquidity and investor confidence.
• Employees: The discontinuation of the 401(k) safe harbor matching contribution effective June 1, 2025, negatively impacts employee benefits.
• Creditors: The company has a working capital deficit and a going concern warning, indicating elevated risk for creditors, although all outstanding debt is current as of June 30, 2025.
• Patients: Clinical trial delays and terminations (e.g., AMP-270, ovarian cancer study) may impact patient access to potential therapies. The delay in Ampligen approval in Argentina also affects CFS patients there.
• Partners: Economic conditions in Argentina (hyper-inflation, peso devaluation) have made CFS treatment costs prohibitive, impacting the partnership with Filaxis and its commercialization efforts for Ampligen.

Next Steps

• Regain compliance with NYSE American's stockholders' equity requirement of $6.0 million or more by June 11, 2026.
• Obtain additional funding to meet anticipated operational cash needs and fund current and future clinical trials.
• Seek senior co-development partners with capital and expertise to commercialize Ampligen and Alferon N Injection.
• Continue clinical trials for Ampligen in pancreatic cancer, including the ongoing DURIPANC study.
• Pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist, seeking collaborative grants.
• Develop a comprehensive response to the FDA and a plan for a confirmatory trial for Ampligen in ME/CFS, focusing on specific symptoms.
• Complete the validation of the polymer production process with Sterling Pharma Solutions for Ampligen manufacturing.
• Identify new manufacturing approach and submit satisfactory stability and quality release data to the FDA to resume commercial sales of Alferon N Injection.
• Address the potential reinstatement of BioLife Plasma Services, L.P.'s counterclaim for $96,000.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial stockholders' deficit of ($6.5) million, a significant decline in cash and marketable investments, and an explicit 'going concern' warning. While a recent reverse stock split allowed relisting on the NYSE American and an $8.0 million capital raise provides a temporary cash infusion, these measures do not fundamentally resolve the underlying issues of consistent operating losses and a persistent need for external financing. The discontinuation of the 401(k) match and the suspension/termination of key clinical trials due to funding highlight operational challenges. The high risk of further dilution, potential future delisting, and the company's inability to generate material revenues make it a highly speculative investment. A seasoned investor would recognize the significant downside risk and the precarious financial position, warranting a strong sell recommendation.

Keywords

Ampligen, Pancreatic Cancer, ME/CFS, Post-COVID Conditions, Clinical Trials, Biotechnology, Immunotherapy, Antiviral, SEC Filing, 10-Q, NYSE American, Reverse Stock Split, Going Concern, Capital Raise, Pharmaceuticals, Oncology, Rintatolimod, Alferon N Injection